tiprankstipranks
Plus Therapeutics Inc (PSTV)
NASDAQ:PSTV

Plus Therapeutics (PSTV) Income Statement

535 Followers

Plus Therapeutics Income Statement

Last quarter (Q1 2024), Plus Therapeutics's total revenue was $1.68M, an increase of 648.66% from the same quarter last year. In Q1, Plus Therapeutics's net income was $-3.26M. See Plus Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 5.28M$ 4.91M$ 224.00K-$ 303.00K$ 7.00M
Cost of Revenue
------
Gross Profit
$ 5.28M$ 4.91M$ 224.00K---
Operating Expense
$ 18.04M$ 18.23M$ -19.94M$ 12.43M$ 9.89M$ 10.65M
Operating Income
$ -12.76M$ -13.32M$ -19.71M$ -12.43M$ -9.58M$ -3.66M
Net Non Operating Interest Income Expense
$ -5.00K$ 5.00K$ -564.00K$ -913.00K$ -1.06M$ -1.80M
Other Income Expense
$ 2.00K-$ -1.00K$ 60.00K$ 2.40M$ 2.17M
Pretax Income
$ -12.77M$ -13.32M$ -20.27M$ -13.40M$ -8.24M$ -3.28M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -12.77M$ -13.32M$ -20.27M$ -13.40M$ -8.24M$ -11.44M
Basic EPS
$ -2.48$ -4.24$ -0.77$ -1.11$ -1.86$ -8.27
Diluted EPS
$ -2.48$ -4.24$ -0.77$ -16.65$ -1.86$ -8.27
Basic Average Shares
$ 44.86M$ 3.14M$ 26.26M$ 805.95K$ 4.43M$ 1.38M
Diluted Average Shares
$ 44.86M$ 3.14M$ 26.26M$ 805.95K$ 4.43M$ 1.38M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 18.04M$ 18.23M$ -19.94M$ 12.43M$ 9.89M$ 10.65M
Net Income From Continuing And Discontinued Operation
$ -12.77M$ -13.32M$ -20.27M$ -13.40M$ -8.24M$ -10.89M
Normalized Income
$ -1.17M---$ -8.24M$ -5.46M
Interest Expense
----$ 1.11M$ 1.85M
EBIT
$ -12.40M$ -12.92M$ -19.56M$ -12.47M$ -7.13M$ -1.43M
EBITDA
$ -11.46M$ -11.99M$ -18.46M$ -11.50M$ -6.77M$ -532.00K
Currency in USD

Plus Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis